Non-Hodgkin’s Lymphoma
Show Only Open Trials
1.
CALGB 50901: A Phase II Trial of Ofatumumab (CALGB IND #112390) in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Untreated Follicular Lymphoma
- Protocol ID: CALGB 50901
2.
S1108: A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
- Study Status: Open to Enrollment
- Sponsor: SWOG
- Disease Status and/or Stage: Relapsed/Refractory Peripheral T-Cell non-Hodgkin Lymphoma
3.
Phase I/II Study of Veltuzumab Combined with 90Y-Epratuzumab Tetraxetan in Patients with Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Immunomedics
4.
Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
- Study Status: Open to Enrollment
- Sponsor: Calistoga
- Disease Status and/or Stage: Refractory Indolent B-cell non-Hodgkin Lymphoma
5.
CALGB 50904: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC #681239, IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Untreated Follicular Lymphoma
- Protocol ID: CALGB 50904
6.
Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- Study Status: Open to Enrollment
- Sponsor: Immunomedics
- Disease Status and/or Stage: Untreated or Relapsed Chronic Lymphocytic Leukemia
7.
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Refractory De Novo diffuse Large B-Cell Lymphoma (PCYC 1106)
- Study Status: Open to Enrollment
- Sponsor: Pharmacyclics
- Disease Status and/or Stage: Relapsed or Refractory de Novo Diffuse Large B-cell Lymphoma (DLBCL)
8.
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients with Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Millennium
- Disease Status and/or Stage: Relapsed or Refractory Lymphoma (non-Hodgkin and Hodgkin)
9.
Coping with Lymphoma to Enhance Adjustment and Reduce Stress in Survivors (CLEAR Stress)
- Study Status: Open to Enrollment
- Sponsor: Agency for Healthcare Research and Quality; Weill Cornell Medical College
10.
Phase II Study of Lenalidomide plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Untreated Mantle Cell Lymphoma
11.
Phase I/II Trial of Azacytidine + R-CHOP in Diffuse Large B-Cell Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Diffuse Large B-Cell Lymphoma (DLBCL)
12.
Phase I/II study of combination epigenetic therapy with azacitidine and vorinostat in patients with relapsed and refractory DLBCL
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
13.
A long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
- Study Status: Open to Enrollment
- Sponsor: Pharmacyclics, Inc.
14.
Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients with Follicular Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Follicular Lymphoma
15.
An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
- Study Status: Open to Enrollment
- Sponsor: Millennium Pharmaceuticals
- Disease Status and/or Stage: Previously untreated Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
16.
Phase 1 Study of PD 0332991 Plus Bortezomib in Patients with Previously Treated Mantle Cell Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Mantle Cell Lymphoma (MCL)
17.
CALGB 50803: A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC #703813, IND#70116) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Untreated Follicular Lymphoma
18.
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Pharmacyclics
- Disease Status and/or Stage: Mantle Cell Lymphoma (MCL)
19.
BMT CTN 0701: A Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response
- Study Status: Open to Enrollment
- Sponsor: National Heart, Lung and Blood Institute (NHLBI); National Cancer Institute
- Disease Status and/or Stage: Relapsed Follicular Non-Hodgkin's Lymphoma
20.
Phase 1 Study of Radiosensitization using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma receiving Radioimmunotherapy
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed or Refractory Non-Hodgkin's Lymphoma
21.
Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-Cell Lymphomas
- Study Status: Open to Enrollment
- Sponsor: National Cancer Institute
- Disease Status and/or Stage: Relapsed or Refractory Mantle Cell or Diffuse Large B-Cell Lymphoma
22.
A Phase II, Single Institution, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of a Single Agent Dasatinib (Sprycel®) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
23.
CALGB 50303: Phase III Randomized Study of R-CHOP vs. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B; National Cancer Institute
- Disease Status and/or Stage: Untreated De Novo Diffuse Large B-Cell Lymphoma with Stage II, III or IV Disease
24.
Early Response Assessment in Patients with Diffuse Large B-Cell Lymphoma Using 18-fluoro-2-deoxyglucose positron emission tomography (FDG-PET)
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Untreated CD20+ Diffuse Large B-Cell Lymphoma (DLBCL) of Any Stage
25.
CALGB 50401: A Randomized Phase II Trial of Rituximab vs. Lenalidomide (Revlimid, CC-5013) (IND #73034) vs. Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) After Relapse from a Rituximab-Containing Regimen
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B; National Cancer Institute
- Disease Status and/or Stage: Recurrent Follicular Non-Hodgkin's Lymphoma
26.
Phase I trial of anti-CD74 (hLL1) Antibody Therapy in B-cell malignancies
- Study Status: Closed to Enrollment
- Sponsor: Weill Cornell Medical College; Immunomedics, Inc.
27.
A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients with Select, Relapsed or Refractory Hematologic Malignancies
- Study Status: Closed to Enrollment
- Sponsor: Calistoga Pharmaceuticals
- Disease Status and/or Stage: Relapsed or Refractory Hematological Malignancies
